Approved agents for metastatic breast cancer

Seminars in Oncology

Volumn 38, Issue SUPPL. 2, 2011, Pages S3-

  Fornier, Monica N ^a,b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTIMA; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ERIBULIN; ETOPOSIDE; GEMCITABINE; IRINOTECAN; IXABEPILONE; NAVELBINE; PACLITAXEL; PEMETREXED; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; VINORELBINE DITARTRATE;

ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; HORMONAL THERAPY; HUMAN; METASTATIC BREAST CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79956202133     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.04.003     Document Type: Conference Paper

References (26)

1. Xeloda [package insert] 2009 Genentech, Inc South San Francisco
2. J.L. Blum, V. Dieras, and P.M. Lo Russo Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients Cancer 92 2001 1759 1768 (Pubitemid 32952493)
3. P. Reichardt, G. Von Minckwitz, and O.C. Thuss-Patience Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy Ann Oncol 14 2003 1227 1233 (Pubitemid 37039048)
4. P. Fumoleau, R. Largillier, and C. Clippe Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer Eur J Cancer 40 2004 536 542 (Pubitemid 38220770)
5. W.B. Ershler Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer Oncologist 11 2006 325 335
6. J. Cortes, and J. Baselga Targeting the microtubules in breast cancer beyond taxanes: the epothilones Oncologist 12 2007 271 280 (Pubitemid 46556793)
7. Ixempra [package insert] 2010 Bristol-Myers Squibb Bridgewater, NJ
8. S. Goodin, M.P. Kane, and E.H. Rubin Epothilones: mechanism of action and biologic activity J Clin Oncol 22 2004 2015 2025 (Pubitemid 41095195)
9. X. Pivot, A. Dufresne, and C. Villanueva Efficacy and safety of ixabepilone, a novel epothilone analogue Clin Breast Cancer 7 2007 543 549 (Pubitemid 46725246)
10. M. Campone, C. Dittrich, and T. Cufer Phase II study of the novel epothilone sagopilone (ZK-EPO) in patients with progressive metastatic breast cancer Cancer Res Suppl 24 2009 69 Abstract 6107
11. K. Gerth, N. Bedorf, G. Hfle, H. Irschik, and H. Reichenbach Epothilones A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria) production, physico-chemical and biological properties J Antibiot (Tokyo) 49 1996 560 563 (Pubitemid 26235665)
12. N. Denduluri, J.A. Low, and J.L. Lee Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes J Clin Oncol 25 2007 3421 3427 (Pubitemid 47310878)
13. E.A. Perez, G. Lerzo, and P. Xavier Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine J Clin Oncol 25 2007 3407 3414 (Pubitemid 47310876)
14. H. Roch, L. Yelle, and F. Cognetti Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy J Clin Oncol 25 2007 3415 3420 (Pubitemid 47310877)
15. E. Thomas, J. Tabernero, and M. Fornier Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer J Clin Oncol 25 2007 3399 3406 (Pubitemid 47310875)
16. H.H. Roch, J. Sparano, and V. Valero Ixabepilone (Ixa) and capecitabine (C) in patients (pts) with triple-negative breast cancer (TNBC): a retrospective analysis of phase 2 and phase 3 clinical studies [abstract 299P] Ann Oncol 21 Suppl 8 2010 viii103
17. L.T. Vadhat, E. Thomas, and H. Roche Ixabepilone (Ixa)-associated peripheral neuropathy (PN): retrospective review of data from phase II and III clinical trials [abstract 320P] Ann Oncol 21 Suppl 8 2010 viii
18. E.S. Thomas, H.L. Gomez, and R.K. Li Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment J Clin Oncol 25 2007 5210 5217 (Pubitemid 350232252)
19. J.A. Sparano, E. Vrdoljak, and O. Rixe Randomised phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 28 2010 3256 3263
20. E. Perez Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance Mol Cancer Ther 8 2009 2086 2095
21. L.T. Vahdat, B. Pruitt, and C.J. Fabian Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 27 2009 2954 2961
22. M.A. Jordan, K. Kamath, and T. Manna The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth Mol Cancer Ther 4 2005 1086 1095 (Pubitemid 41079102)
23. J. Cortes, L. Vahdat, and J.L. Blum Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine J Clin Oncol 28 2010 3922 3928
24. Twelves C, Loesch D, Blum JL, et al. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. Paper presented at the 46th Annual Meeting of the American Society of Clinical Oncology; 2010 June 48; Chicago, IL.
25. Halaven [package insert] 2010 Eisai Inc South San Francisco
26. J. Baselga, P. Gomez, and A. Awada Eribulin mesylate (E7389) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC): subgroup analysis from the EMBRACE study Ann Oncol 21 suppl 8 2010 viii-95 Suppl 2750